Tg Therapeutics (TGTX) Cash from Investing Activities (2011 - 2026)

Tg Therapeutics' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$9.9 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 23.74% year-over-year to -$9.9 million; the TTM figure through Mar 2026 stood at $16.9 million (up 457.77% YoY), while the FY2025 annual figure was $13.8 million, up 1431.95% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$9.9 million, up from -$15.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $46.4 million in Q3 2025, with the low at -$44.8 million in Q4 2023.
• The 5-year median for Cash from Investing Activities is -$6.2 million (2023), against an average of -$4.0 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities sank 8396.3% in 2022, then jumped 596.71% in 2025.
• Tg Therapeutics' Cash from Investing Activities stood at $16.3 million in 2022, then sank by 375.09% to -$44.8 million in 2023, then soared by 135.28% to $15.8 million in 2024, then slumped by 199.05% to -$15.6 million in 2025, then jumped by 36.92% to -$9.9 million in 2026.
• Business Quant data shows TGTX's Cash from Investing Activities at -$9.9 million in Q1 2026, -$15.6 million in Q4 2025, and $46.4 million in Q3 2025.